Base excision repair, the redox environment and therapeutic implications

Current Molecular Pharmacology

Volumn 5, Issue 1, 2012, Pages 88-101

  Storr, S J ^a   Woolston, C M ^a   Martin, S G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Base excision repair; Cancer; Homeostasis; Redox

Indexed keywords

ANTIOXIDANT; CYCLINE; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; DNA GLYCOSYLTRANSFERASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HYDROGEN PEROXIDE; HYDROXYL RADICAL; MANGANESE SUPEROXIDE DISMUTASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PEROXIREDOXIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; THIOREDOXIN;

CANCER RISK; CANCER THERAPY; CARCINOGENESIS; DNA DAMAGE; DNA REPLICATION; DNA TRANSCRIPTION; EXCISION REPAIR; GENE MUTATION; HOMEOSTASIS; HUMAN; NEOPLASM; OXIDATION REDUCTION REACTION; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; REVIEW; THERAPY RESISTANCE;

ANTINEOPLASTIC AGENTS; DNA DAMAGE; DNA GLYCOSYLASES; DNA REPAIR; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; GLUTATHIONE PEROXIDASE; HUMANS; NEOPLASMS; OXIDATIVE STRESS; PEROXIREDOXINS; REACTIVE OXYGEN SPECIES; SUPEROXIDE DISMUTASE;

EID: 84855851655     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467211205010088     Document Type: Review

References (161)

1. Dröge, W. Free radicals in the physiological control of cell function. Physiol. Rev., 2002, 82, 47-95.
2. D'Errico, M.; Parlanti, E.; Dogliotti, E. Mechanism of oxidative DNA damage repair and relevance to human pathology. Mutat. Res., 2008, 659, 4-14.
3. Wu, W-S. The signalling mechanism of ROS in tumour progression. Cancer Metastasis Rev., 2006, 25, 695-705.
4. Valko, M.; Rhodes, C.J.; Moncol, J.; Izakovic, M.; Mazur, M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem. Biol. Interact., 2006, 160, 1-40.
5. Karihtala, P.; Soini, Y. Reactive oxygen species and antioxidant mechanisms in human tissues and their relationship to malignancies. APMIS, 2007, 115, 81-103.
6. Pastor, N.; Weinstein, H.; Jamison, E.; Brenowitz, M. A detailed interpretation of OH radical footprints in a TBP-DNA complex reveals the role of dynamics in the mechanism of sequence specific binding. J. Mol. Biol., 2000, 304, 55-68.
7. Beckman, J.A.; Beckman, T.W.; Chen, J.; Marshall, P.A. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. USA, 1990, 87, 1620-1624.
8. Stamler, J.S.; Singel, D.J.; Loscalzo, J. Biochemistry of nitric oxide and its redox-activated forms. Science, 1992, 258(5090), 1898-1902.
9. Ferrer-Sueta, G.; Radi, R. Chemical biology of peroxynitrite: kinetics, diffusion, and radicals. ACS Chem. Biol., 2009, 4, 161-177
10. Burney, S.; Caulfield, J.L.; Niles, J.C.; Wishnok, J.S.; Tannenbaum, S.R. The chemistry of DNA damage from nitric oxide and peroxynitrite. Mutat. Res., 1999, 424, 37-49.
11. Jacob, C.; Knight, I.; Winyard, P.G. Aspects of the biological redox chemistry of cysteine: from simple redox responses to sophisticated signalling pathways. Biol. Chem., 2006, 387, 1385-1397.
12. Davies, K.J. The broad spectrum of responses to oxidants in proliferating cells: a new paradigm for oxidative stress. IUBMB Life, 1999, 48, 41-47.
13. Brown, N.S.; Bicknell, R. hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on growth, metastatic potential and response to therapy in breast cancer. Breast Cancer Res., 2001, 3, 323-327.
14. Behrend, L.; Henderson, G.; Zwacka, R.M. Reactive oxygen species in oncogenic transformation. Biochem. Soc. Trans., 2003, 31, 1441-1444.
15. Totter, J.R. Spontaneous cancer and its possible relationship to oxygen metabolism. Proc. Natl. Acad. Sci. USA, 1980, 77, 1763-1767.
16. Szatrowski, T.P.; Nathan, C.F. Production of large amounts of hydrogen peroxide by human tumour cells. Cancer Res., 1991, 51, 794-798.
17. Cooke, M.S.; Evans, M.D.; Dizdaroglu, M.; Lunec, J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB, 2003, 17, 1195-1214.
18. Wiseman, H.; Halliwell, B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem. J., 1996, 313, 17-29.
19. Demple, B.; Harrison, L. Repair of oxidative damage to DNA: enzymology and biology. Annu. Rev. Biochem., 1994, 63, 915-948.
20. Barzilai, A.; Yamamoto, K-I. DNA damage responses to oxidative stress. DNA Repair, 2004, 3, 1109-1115.
21. Wilson III, D.M.; Bohr, V.A. The mechanisms of base excision repair and its relationship to ageing and disease. DNA Repair (Amst.), 2007, 6(4), 544-559.
22. Fan, J.; Wilson III, D.M. Protein-protein interactions and posttranslational modifications in mammalian base excision repair. Free Radic. Biol. Med., 2005, 38(9), 1121-1138.
23. Dizdaroglu, M.; Karahalil, B.; Sentürker, S.; Buckley, T.J.; Roldán-Arjona, T. Excision of products of oxidative DNA base damage by human NTH1 protein. Biochemistry, 1999, 38, 243-246.
24. Mokkapati, S.K.; Wiederhold, L.; Hazra, T.K.; Mitra, S. Stimulation of DNA glycosylase activity of OGG1 by NEIL1: functional collaboration between two human DNA glycosylases. Biochemistry, 2004, 43, 11596-11604.
25. Izumi, T.; Hazra, T.K.; Boldogh, I.; Tomkinson, A.E.; Park, M.S.; Ikeda, S.; Mitra, S. Requirement for human AP endonuclease 1 for repair of 3'-blocking damage at DNA single-strand breaks induced by reactive oxygen species. Carcinogenesis, 2000, 21(7), 1329-1334.
26. Loeb, L.A.; Preston, B.D. Mutagenesis by apurinic/apyrimidinic sites. Ann. Rev. Genet., 1986, 20, 201-230.
27. D'Errico, M.; Parlanti, E.; Teson, M.; Bernardes de Jesus, B.M.; Degan, P.; Calcagnile, A.; Jaruga, P.; Bjørås, M.; Crescenzi, M.; Pedrini, A.M.; Egly, J-M.; Zambruno, G.; Stefanini, M.; Dizdaroglu, M.; Dogliotti, E. New functions of XPC in the protection of human skin cells from oxidative damage. EMBO J., 2006, 25, 4305-4315
28. Wood, Z.A.; Poole, L.B.; Karplus, A. Peroxiredoxin evolution and the regulation of hydrogen peroxide signalling. Science, 2003, 300, 650-653.
29. Biteau, B.; Labarre, J.; Toledano, M.B. ATP-dependent reduction of cysteine-sulphinic acid by S. cerevisiae sulphiredoxin. Nature, 2003, 425, 980-984.
30. Neumann, C.A.; Fang, Q. Are peroxiredoxins tumor suppressors? Curr. Opin. Pharmacol., 2007, 7, 375-380.
31. Neumann, C.A.; Cao, J.; Manevich, Y. Peroxiredoxin 1 and its role in cell signaling. Cell Cycle, 2009, 8, 4072-4078.
32. Koo, K.H.; Lee, S.; Jeong, S.Y.; Kim, E.T.; Kim, K.; Song, K.; Chae, H.Z. Regulation of thioredoxin peroxidase activity by Cterminal truncation. Arch. Biochem. Biophys., 2002, 397, 312-318.
33. Chang, T.S.; Jeong, W.; Choi, S.Y.; Yu, S.; Kang, S.W.; Rhee, S.G. Regulation of peroxiredoxin I activity by Cdc2-mediated phosphorylation. J. Biol. Chem., 2002, 277, 25370-25376.
34. Kinnula, V.; Lehtonen, S.; Sormunen, R.; Kaarteenaho-Wiik, R.; Kang, S.; Rhee, S.; Soini, Y. Overexpression of peroxiredoxins I, II, III, V and VI in malignant mesothelioma. J. Pathol., 2002, 196, 316-323.
35. Karihtala, P.; Mantyniemi, A.; Kang, S.; Kinnula, V.; Soini, Y. Peroxiredoxins in breast carcinoma. Clin. Cancer Res., 2003, 9, 3418-3424.
36. Choi, J.; Kim, T.; Kim, S.; Baek, S.; Kim, J.; Lee, S.; Kim, J. Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res., 2002, 22, 3331-3335.
37. Zhang, B.; Wang, Y.; Su, Y. Peroxiredoxins, a novel target in cancer radiotherapy. Cancer Lett., 2009, 286, 154-160.
38. Neumann, C.A.; Krause, D.S.; Carman, C.V.; Das, S.; Dubey, D.P.; Abraham, J.L.; Bronson, R.T.; Fujiwara, Y.; Orkin, S.H.; Van Etten, R.A. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature, 2003, 424, 561-565.
39. Kropotov, A.; Serikov, V.; Suh, J.; Smirnova, A.; Bashkirov, V.; Zhivotovsky, B.; Tomilin, N. Constitutive expression of the human peroxiredoxin V gene contributes to protection of the genome from oxidative DNA lesions and to suppression of transcription of noncoding DNA. FEBS J., 2006, 273, 2607-2617.
40. Miyazaki, K.; Noda, N.; Okada, S.; Hagiwara, Y.; Miyata, M.; Sakurabayashi, I.; Yamaguchi, N.; Sugimura, T.; Terada, M.; Wakasugi, H. Elevated serum level of thioredoxin in patients with hepatocellular carcinoma. Biotherapy, 1998, 11, 277-288.
41. Lichtenfels, R.; Kellner, R.; Atkins, D.; Bukur, J.; Ackermann, A.; Beck, J.; Brenner, W.; Melchior, S.; Seliger, B. Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. Biochim. Biophys. Acta., 2003, 1646, 21-31.
42. Lincoln, D.; Ali Emadi, E.; Tonissen, K.; Clarke, F. The thioredoxin-thioredoxin reductase system: over-expression in human cancer. Anticancer Res., 2003, 23, 2425-2433.
43. Raffel, J.; Bhattacharyya, A.K.; Gallegos, A.; Cui, H.; Einspahr, J.G.; Alberts, D.S.; Powis, G. Increased expression of thioredoxin-1 in human colorectal cancer is associated with decreased patient survival. J. Lab. Clin. Med., 2003, 142, 46-51.
44. Soini, Y.; Kahlos, K.; Näpänkangas, U.; Kaarteenaho-Wiik, R.; Säily, M.; Koistinen, P.; Pääakkö, P.; Holmgren, A.; Kinnula, V.L. Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma. Clin. Cancer Res., 2001, 7, 1750-1757.
45. Powis, G.; Montfort, W. Properties and biological activities of thioredoxins. Annu. Rev. Biophys. Biomol. Struct., 2001, 30, 421-455.
46. Biaglow, J.; Miller, R. The thioredoxin reductase/thioredoxin system. Cancer Biology & Therapy, 2005, 4, 6-13.
47. Gromer, S.; Urig, S.; Becker K. The thioredoxin system-from science to clinic. Med. Res. Rev., 2004, 24, 40-89.
48. Ueno, M.; Matsutani, Y.; Nakamura, H.; Masutani, H.; Yagi, M.; Yamashiro, H.; Kato, H.; Inamoto, T.; Yamauchi, A.; Takahashi, R.; Yamaoka, Y.; Yodoi, J. Possible association of thioredoxin and p53 in breast cancer. Immunol. Lett., 2000, 75, 15-20.
49. Naito, S.; Koga, H.; Yokomizo, A.; Sakamoto, N.; Kotoh, S.; Nakashima, M.; Kiue, A.; Kuwano, M. Molecular analysis of mechanisms regulating drug sensitivity and the development of new chemotherapy strategies for genitourinary carcinomas. World J. Surg., 2000, 24, 1183-1186.
50. Brigelius-Flohé, R.; Kipp, A. Glutathione peroxidases in different stages of carcinogenesis. Biochim. Biophys. Acta, 2009, 1790(11), 1555-1568.
51. Zhang, Y.; Ikeno, Y.; Qi, W.; Chaudhuri, A.; Li, Y.; Bokov, A.; Thorpe, S.R.; Baynes, J.W.; Epstein, C.; Richardson, A.; Van Remmen, H. Mice deficient in both Mn superoxide dismutase and glutathione peroxidase-1 have increased oxidative damage and a greater incidence of pathology but no reduction in longevity. J. Gerontol. A. Biol. Sci. Med. Sci., 2009, 64, 1212-1220.
52. Lu, L.; Oveson, B.C.; Jo, Y-J.; Lauer, T.W.; Usui, S.; Komeima, K.; Xie, B.; Campochiaro, P.A. increased expression of glutathione peroxidase 4 strongly protects retina from oxidative damage. Antioxid. Redox Signal., 2009, 11, 715-724.
53. Bai, F.; Nakanishi, Y.; Kawasaki, M.; Takayama, K.; Yatsunami, J.; Pei, X.H.; Tsuruta, N.; Wakamatsu, K.; Hara, N. Immunohistochemical expression of glutathione S-transferase-Pi can predict chemotherapy response in patients with non small cell lung carcinoma. Cancer, 1996, 78, 416-421.
54. Curtis, C.D.; Thorngren, D.L.; Nardulli, A.M. Immunohistochemical analysis of oxidative stress and DNA repair proteins in normal mammary and breast cancer tissues. BMC Cancer, 2010, 10, 9.
55. Fernandes, A.P.; Capitanio, A.; Selenius, M.; Brodin, O.; Rundlöf, A-K.; Björnstedt, M. Expression profiles of thioredoxin family proteins in human lung cancer tissue: correlation with proliferation and differentiation. Histopathology, 2009, 54, 313-320.
56. Grogan, T.M.; Fenoglio-Prieser, C.; Zeheb, R.; Bellamy, W.; Frutiger, Y.; Vela, E.; Stemmerman, G.; Macdonald, J.; Richter, L.; Gallegos, A.; Powis, G. Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum. Pathol., 2000, 31, 448-475.
57. Kahlos, K.; Pääkkö, P.; Kurttila, E.; Soini, Y.; Kinnula, V.L. Manganese superoxide dismutase as a diagnostic marker for malignant pleural mesothelioma. B. J. Cancer., 2000, 82, 1022-1029.
58. Woolston, C.M.; Zhang, L.; Evans, H.; Al-Attar, A.; Shehata, M.; Balls, G., Chan, S.Y.; Martin, S.G. Thioredoxin and related redox systems as targets in breast cancer. Breast Cancer Res., 2010, 12(Suppl. 1), P29.
59. Woolston, C.M.; Al-Attar, A.; Storr, S.J.; Ellis, I.O.; Morgan, D.A.; Martin, S.G. Redox protein expression predicts radiotherapeutic response in early stage invasive breast cancer patients. Int. J. Radiat. Oncol. Biol. Phys., 2011, 79, 1532-1540.
60. Woolston, C.M.; Deen, S.; Al-Attar, A.; Shehata, M.; Chan, S.Y.; Martin, S.G. Redox protein expression predicts progression-free and overall survival in ovarian cancer patients treated with platinum based chemotherapy. Free Radic. Biol. Med., 2010, 49, 1263-1272.
61. Woolston, C.M.; Storr, S.J.; Ellis, I.O.; Morgan, D.A.; Martin, S.G. Expression of thioredoxin system and related peroxiredoxin proteins is associated with clinical outcome in radiotherapy in breast cancer. Radiother. Oncol., 2011, 100(2), 308-313.
62. Dally, H.; Hartwig, A. Induction and repair inhibition of oxidative DNA damage by nickel(II) and cadmium(II) in mammalian cells. Carcinogenesis, 1997, 18, 1021-1026.
63. Bravard, A.; Vacher, M.; Gouget, B.; Coutant, A.; Hillairet de Boisferon, F.; Radicella, J.P. Redox regulation of human OGG1 activity in response to cellular oxidative stress. Mol. Cell. Biol., 2006, 26, 7430-7436.
64. Li, H.; Hao, X.; Zhang, W.; Wei, Q.; Chen, K. The hOGG1 Ser326Cys polymorphism and lung cancer risk: a meta-analysis. Cancer Epidemiol. Biomarkers Prev., 2008, 17, 1739-1745.
65. Bravard, A.; Vacher, M.; Moritz, E.; Vaslin, L.; Hall, J.; Epe, B.; Radicella, J.P. Oxidation status of human OGG1-S326C polymorphic variant determines cellular DNA repair capacity. Cancer Res., 2009, 69, 3642-3649.
66. Hegde, V.; Wang, M.; Deutsch, W.A. Human ribosomal protein S3 interacts with DNA base excision repair proteins hAPE/Ref-1 and hOGG1. Biochemistry, 2004, 43, 14211-14217.
67. Hegde, V.; Wang, M.; Mian, I.S.; Spyres, L.; Deutsch, W.A. The high binding affinity of human ribosomal protein S3 to 7,8-dihydrp-8-oxoguanine is abrogated by a single amino acid change. DNA Repair, 2006, 5(7), 810-815.
68. Wan, F.; Anderson, D.E.; Barnitz, R.A.; Snow, A.; Bidere, N.; Zheng, L.; Hegde, V.; Lam, L.T.; Staudt, L.M.; Levens, D.; Deutsch, W.A.; Lenardo, M.J. Ribosomal protein S3: A KH domain subunit in NF-KB complexes that mediates selective gene regulation. Cell, 2007, 131, 927-939.
69. Yadavilli, S.; Mayo, L.D.; Higgins, M.; Lain, S.; Hegde, V.; Deutsch, W.A. Ribosomal protein S3: A multi-functional protein that interacts with both p53 and MDM2 through its KH domain. DNA Repair, 2009, 8, 1215-1224.
70. Demple, B.; Herman, T.; Chen, T.S. Cloning and expression of APE1, the cDNA encoding the major human apurinic endonuclease: Definition of a family of DNA repair enzymes. Proc. Natl. Acad. Sci. USA, 1991, 88, 11450-11454.
71. Robson, C.N.; Hickson, I.D. Isolation of cDNA clones encoding a human apurinic/apyrimidinic endonuclease that corrects DNA repair and mutagenesis defects in E. coli xth (exonuclease III) mutants. Nucleic Acids Res., 1991, 19, 5519-5523.
72. Xanthoudakis, S.; Curran, T. Identification and characterisation of Ref-1, a nuclear protein that facilitates AP-1 DNA binding activity. EMBO J., 1992, 11, 653-665.
73. Xanthoudakis, S.; Miao, G.G.; Curran, T. The redox and DNArepair activities of Ref-1 are encoded by nonoverlapping regions. Proc. Natl. Acad. Sci. USA, 1994, 91, 23-27.
74. Kelley, M.R.; Parsons, S.H. Redox regulation of the DNA function of the human AP endonuclease APE1/Ref1. Antioxid. Redox Signal., 2001, 3, 671-683.
75. Ramana, C.C.; Boldogh, I.; Izumi, T.; Mitra, S. Activation of apurinic/apyrimidinic endonuclease in human cells by reactive oxygen species and its correlation with their adaptive response to genotoxicity of free radicals. Proc. Natl. Acad. Sci. USA, 1998, 95, 5061-5066.
76. Yang, S.; Misner, B.J.; Chiu, R.J.; Meyskens, F.L. Redox effector factor 1, combined with reactive oxygen species, plays an important role in the transformation of JB6 cells. Carcinogenesis, 2007, 28, 2382-2390.
77. Pines, A.; Perrone, L.; Bivi, N.; Romanello, M.; Damante, G.; Gulisano, M.; Kelley, M.R.; Quadrifoglio, F.; Tell, G. Activation of APE1/Ref-1 is dependent upon reactive oxygen species generated after purinergic receptor stimulation by ATP. Nucleic Acids Res., 2005, 33, 4379-4394.
78. Hsieh, M.M.; Hegde, V.; Kelley, M.R.; Deutsch, W.A. activation of APE1/Ref-1 redox activity is mediated by reactive oxygen species and PKC phosphorylation. Nucleic Acids Res., 2001, 29, 3116-3122.
79. Dou, H.; Mitra, S.; Hazra, T.K. Repair of oxidised bases in DNA bubble structures by human DNA glycosylases NEIL1 and NEIL2. J. Biol. Chem., 2003, 278, 49679-49684.
80. Das, S.; Chattopadhyay, R.; Bhakat, K.K.; Boldogh, I.; Kohno, K.; Prasad, R.; Wilson, S.H.; Hazra, T.K. Stimulation of NEIL2-mediated oxidative base excision repair via YB-1 interaction during oxidative stress. J. Biol. Chem., 2007, 282, 28474-28484.
81. Cuneo, M.J.; London, R.E. Oxidation state of the XRCC1 Nterminal domain regulates DNA polymerase β binding affinity. Proc. Natl. Acad. Sci. USA, 2010, 107, 6805-6810.
82. Bennett, S.M.; Neher, T.M.; Shatilla, A.; Turchi, J.J. Molecular analysis of Ku redox regulation. BMC Mol. Biol., 2009, 10, 86.
83. Andrews, B.J.; Lehman, J.A.; Turchi, J.J. Kinetic analysis of the Ku-DNA binding activity reveals a redox-dependent alteration in protein structure that stimulates dissociation of the Ku-DNA complex. J. Biol. Chem., 2006, 281, 13596-13603.
84. Ayene, I.S.; Stamato, T.D.; Mauldin, S.K.; Biaglow, J.E.; Tuttle, S.W.; Jenkins, S.F.; Koch, C.J. Mutation in the glucose-6-phosphate dehydrogenase gene leads to inactivation of Ku DNA end binding during oxidative stress. J. Biol. Chem., 2002, 277, 9929-9935.
85. Alexander, A.; Cai, S-L.; Kim, J.; Nanez, A.; Sahin, M.; MacLean, K.H.; Inoki, K.; Guan, K-L.; Shen, J.; Person, M.D.; Kusewitt, D.; Mills, G.B.; Kastan, M.B.; Walker, C.L. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc. Natl. Acad. Sci. USA, 2010, 107, 4153-4158.
86. Men, L.; Roginskaya, M.; Zou, Y.; Wang, Y. Redox-dependent formation of disulphide bonds in human replication protein A. Rapid Commun. Mass Spectrom., 2007, 21, 2743-2749.
87. Das, A.; Hazra, T.K.; Boldogh, I.; Mitra, S.; Bhakat, K.K. Induction of the human oxidised base specific DNA glycosylase by reactive oxygen species. J. Biol. Chem., 2005, 280, 35272-35280.
88. Huang, L.E.; Arany, Z.; Livingston, D.M.; Bunn, H.F. Activation of hypoxia inducible transcription factor depends primarily on the redox-sensitive stabilisation of its alpha subunit. J. Biol. Chem., 1996, 271, 32253-32259.
89. Nishi, T.; Shimizu, N.; Hiramoto, M.; Sato, I.; Yamaguchi, Y.; Hasegawa, M.; Aizawa, S.; Tanaka, H.; Kataoka, K.; Watanabe, H.; Handa, H. Spatial redox regulation of a critical cysteine residue of NFκB in-vivo. J. Biol. Chem., 2002, 277, 44548-44556.
90. Loboda, A.; Stachurska, A.; Dorosz, J.; Wegrzyn, J.; Kozakowska, M; Jozkowicz, A.; Dulak, J. HIF-1 attenuates REF-1 expression in endothelial cells: reversal by siRNA and inhibition of geranylgeranylation. Vascul. Pharmacol., 2010, 51, 133-139.
91. Ziel, K.A.; Grishko, V.; Campbell, C.C.; Breit, J.F.; Wilson, G.L.; Gillespie, M.N. Oxidants in signal transduction: impact on DNA integrity and gene expression. FASEB J., 2005, 19, 387-394.
92. Pastukh, V.; Ruchko, M.; Gorodnya, O.; Wilson, G.L.; Gillespie, M.N. Sequence-specific oxidative base modifications in hypoxiainducible genes. Free Radic. Biol. Med., 2007, 43, 1616-1626.
93. Ruchko, M.V.; Gorodnya, O.M.; Pastukh, V.M.; Swiger, B.M.; Middleton, N.S.; Wilson, G.L.; Gillespie, M.N. Hypoxia-induced oxidative base modifications in the VEGF hypoxia-response element are associated with transcriptionally active nucleosomes. Free Radic. Biol. Med., 2009, 46, 352-359.
94. Hirota, K.; Matsui, M.; Iwata, S.; Nishiyama, A; Mori, K.; Yodoi, J. AP-1 transcriptional activity is regulated by a direct association between thioredoxin and Ref-1. Proc. Natl. Acad. Sci. USA, 1997, 94, 3633-3638.
95. Ueno, M.; Masutani, H.; Yamauchi, A.; Jun Arai, R.; Hirota, K.; Sakai, T.; Inamoto, T.; Yamaoka, Y.; Yodo, J.; Nikaido, T. Thioredoxin-dependent Redox Regulation of p53-mediated p21 Activation. J. Biol. Chem., 1999, 274, 35809-35815.
96. Wei, S.J.; Botero, A.; Hirota, K.; Bradbury, C.M.; Markovina, S.; Laszlo, A.; Spitz, D.R.; Goswami, P.C.; Yodoi, J.; Gius, D. Thioredoxin Nuclear Translocation and Interaction with Redox Factor-1 Activates the Activator Protein-1 Transcription Factor in Response to Ionizing Radiation. Cancer Res., 2000, 60, 6688-6695.
97. Liu, H.; Colavitti, R.; Rovira, I.I.; Finkel, T. Redox dependent transcriptional regulation. Circ. Res., 2005, 97, 967-974.
98. Levine, A.J. p53, the cellular gatekeeper for growth and division. Cell, 1997, 88, 323-331.
99. Lotum, J.; Peled-Kamar, M.; Groner, Y.; Sachs, L. Cellular oxidative stress and the control of apoptosis by wild-type p53, cytotoxic compounds and cytokines. Proc. Natl. Acad. Sci. USA, 1996, 93, 9166-9171.
100. Seemann, S.; Hainaut, P. Roles of thioredoxin reductase 1 and APE/Red-1 in the control of basal p53 stability and activity. Oncogene, 2005, 24, 3853-3863.
101. Achanta, G.; Huang, P. Role of p53 in sensing oxidative DNA damage in response to reactive oxygen species generating agents. Cancer Res., 2004, 64, 6233-6239.
102. Zhou, J.; Ahn, J.; Wilson, S.H.; Prives, C. A role for p53 in base excision repair. EMBO J., 2001, 20, 914-923.
103. Buzek, J.; Latonen, L.; Kurki, S.; Peltonen, K.; Laiho, M. Redox state of tumour suppressor p53 regulates its sequence specific DNA binding in DNA damaged cells by cysteine 277. Nucleic Acids Res., 2002, 30, 2340-2348.
104. Olovnikov, I.A.; Kravchenko, J.E.; Chumakov, P.M. Homeostatic functions of the p53 tumour suppressor: regulation of energy metabolism and antioxidant defence. Semin. Cancer Biol., 2009, 19, 32-41.
105. Saha, T.; Rih, J.K.; Roy, R.; Ballal, R.; Rosen, E.M. Transcriptional regulation of the base excision repair pathway by BRCA1. J. Biol. Chem., 2010, 285, 19092-19105.
106. Masson, M.; Niedergang, C.; Schreiber, V.; Muller, S.; Menissierde Murcia, J.; de Murcia, G. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol. Cell. Biol., 1998, 18, 3563-3571.
107. Rouleau, M.; Patel, A.; Hendzel, M.J.; Kaufmann, S.H.; Poirier, G.G. PARP inhibition: PARP1 and beyond. Nat. Rev. Cancer, 2010, 10, 293-301.
108. Pacher, P.; Szabo, C. Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease. Am. J. Pathol., 2008, 173, 2-13.
109. Catalgol, B.; Wendt, B.; Grimm, S.; Breusing, N.; Özer, N.K.; Grune, T. chromatin repair after oxidative stress: role of PARP mediated proteasome activation. Free Radic. Biol. Med., 2010, 48, 673-680.
110. Yu, S-W.; Wang, H.; Poitras, M.F.; Coombs, C.; Bowers, W.J.; Federoff, H.J.; Poirier, G. G; Dawson, T.M.; Dawson, V.L. Mediation of poly (ADP-ribose) polymerase-1 dependent cell death by apoptosis inducing factor. Science, 2002, 297, 259-263.
111. Son, Y-O.; Kook, S-H.; Jang, Y-S.; Shi, X.; Lee, J-C. Critical role of poly(ADP-ribose) polymerase-1 in modulating the mode of cell death caused by continuous oxidative stress. J. Cell Biochem., 2009, 108, 989-997.
112. Wondrak, G.G. Redox-directed cancer therapeutics: molecular mechanisms and opportunities Antioxid. Redox Signal., 2009, 11, 3013-3069.
113. Kang, Y-H.; Yi, M-J.; Kim, M-J.; Park, M-T.; Bae S.; Kang, C-M.; Cho, C-K.; Park, I-C.; Park, M-J.; Rhee, C.H.; Hong, S-I.; Cheung, H.Y.; Lee, Y-S.; Lee, S-J. Caspase-independent cell death by arsenic trioxide in human cervical cancer cells: reactive oxygen species mediated poly (ADP-ribose) polymerase-1 activation signals apoptosis-inducing factor release from mitochondria. Cancer Res., 2004, 64, 8960-8967.
114. Sidorkina, O.; Espey, M.G.; Miranda, K.M.; Wink, D.A.; Laval, J. inhibition of poly (ADP-ribose polymerase (PARP) y nitric oxide and reactive nitrogen oxide species. Free Radic. Biol. Med., 2003, 35, 1431-1438.
115. Yu, Z.; Kuncewicz, T.; Dubinsky, W.P.; Kone, B.C. Nitric oxidedependent negative feedback of PARP1 trans-activation of the inducible nitric-oxide synthase gene. J. Biol. Chem., 2006, 281, 9101-9109.
116. Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M.T.D.; Mazur, M.; Telser, J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol., 2007, 39, 44-84.
117. Cook, J.A.; Gius, D.; Wink, D.A.; Krishna, M.C.; Russo, A.; Mitchell, J.B. Oxidative stress, redox, and the tumour microenvironment. Semin. Radiat. Oncol., 2004, 14, 259-266.
118. Pennington, J.D.; Wang, T.J.C.; Nguyen, P.; Sun, L.; Bisht, K.; Smart, D.; Gius, D. Redox-sensitive signalling factors as a novel molecular targets for cancer therapy. Drug Resis. Updates, 2005, 8, 322-330.
119. Renschler, M.F. The emerging role of reactive oxygen species in cancer therapy. Eur. J. Cancer, 40, 1934-1940.
120. Chen, W.; McBride, W.; Iwamoto, K.; Barber, C.; Wang, C.; Oh, Y.; Liao, Y.; Hong, J.; de Vellis, J.; Shau, H. Induction of radioprotective peroxiredoxin-I by ionizing irradiation. J. Neurosci. Res., 2002, 70, 794-798.
121. Smart, D.; Ortiz, K.; Mattson, D.; Bradbury, C.; Bisht, K.; Sieck, L.; Brechbiel, M.; Gius, D. Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress. Cancer Res., 2004, 64, 6716-6724.
122. Bump, E.A.; Brown, J.M. Role of glutathione in the radiation response of mammalian cells in vitro and in vivo. Pharmac. Ther., 1990, 47, 117-136.
123. Kramer, R.A.; Zakher, J.; Kim, G. Role of the glutathione redox cycle in acquired and de novo multidrug resistance. Science, 1988, 241, 694-697.
124. Wartenberg, M.; Hoffmann, E.; Schwindt, H.; Grünheck, F.; Petros, J.; Arnold, J.R.S.; Hescheler, J.; Sauer, H. Reactive oxygen species linked regulation of the multidrug resistance transporter Pglycoprotein in Nox-1 overexpressing prostate tumor spheroids. FEBS lett., 2005, 579, 4541-4549.
125. Anestal, K.; Prast-Nielsen, S.; Cenas, N.; Arner, E.S.J. Cell death by SecTRAPs: Thioredoxin reductase as a prooxidant killer of cells. PLoS ONE, 2008, 3, e1846, 1-16.
126. Pompella, A.; Visvikis, A.; Paolicchi, A.; De Tata, V.; Casini, A.F. The changing faces of glutathione, a cellular protagonist. Biochem. Pharmacol., 2003, 66, 1499-1503.
127. Rebrin, I.; Sohal, R.S. Pro-oxidant shift in glutathione redox state during aging. Adv. Drug Delivery Rev., 2008, 60, 1545-1552.
128. Ravi, D.; Muniyappa, H.; Das, K. Endogenous thioredoxin is required for redox cycling of anthracyclines and p53-dependent apoptosis in cancer cells. J. Biol. Chem., 2005, 280, 40084-40096.
129. Wang, J.; Yi, J. Cancer killing via ROS. Cancer Biol. Ther., 2008, 7, 1875-1884.
130. Caple, F.; Williams, E.A.; Spiers, A.; Tyson, J.; Burtle, B.; Daly, A.K.; Mathers, J.C.; Hesketh, J.E. Inter-individual variation in DNA damage and base excision repair in young, healthy nonsmokers: effects of dietary supplementation and phenotype. Br. J. Nutr., 2009, 103, 1585-1593.
131. Larsson, S.C.; Bergkvist, L.; Wolk, A. Dietary carotenoids and risk of hormone receptor-defined breast cancer in a prospective cohort of Swedish women. Eur. J. Cancer, 2010, 46, 1079-1085.
132. Koran, R.; Hadari-Naor, I.; Zuck, E.; Rotem, C.; Liberman, U.A.; Ravid, A. Vitamin D is a prooxiodant in breast cancer cells. Cancer Res., 2001, 61, 1439-1444.
133. Hyodo, F.; Soule, B.P.; Matsumoto, K-I., Matsumoto, S.; Cook, J.A.; Hyodo, E.; Sowers, A.L.; Krishna, M.C.; Mitchell, J.B. Assessment of tissue redox status using metabolic responsive contrast agents and magnetic resonance imaging. J. Pharm. Pharmacol., 2008, 60, 1049-1060.
134. Hyodo, F.; Matsumoto, K-I.; Matsumoto, A.; Mitchell, J.B.; Krishna, M.C. Probing the intracellular redox status of tumors with magnetic resonance imaging and redox-sensitive contrast agents. Cancer Res., 2006, 66, 9921-9928.
135. Matsumoto, K-I.; Hyodo, F.; Matsumoto, A.; Koretsky, A.P.; Sowers, A.L.; Mitchell, J.B.; Krishna, M.C. High-resolution mapping of tumor redox status by magnetic resonance imaging using nitroxides as redox-sensitive contrast agents. Clin. Cancer Res., 2006, 12, 2455-2462.
136. Hashemy, S.I.; Ungerstedt, J.S.; Avval, F.Z.; Holmgren, A. Motexafin Gadolinium, a tumor-selective drug targeting thioredoxin reductase and ribonucleotide reductase. J. Biol. Chem., 2006, 281, 10691-10697.
137. Evens, A.M. Motexafin gadolinium: a redox-active tumor selective agent for the treatment of cancer. Curr. Opin. Oncol., 2004, 16, 576-580.
138. Mehta, M.P.; Shapiro, W.R.; Phan, S.C.; Gervais, R.; Carrie, C.; Chabot, P.; Patchell, R.A.; Glantz, M.J.; Recht, L.; Langer, C.; Sur, R.K.; Roa, W.H.; Mahe, M.A.; Fortin, A.; Nieder, C.; Meyers, C.A.; Smith, J.A.; Miller, R.A.; Renschler, M.F. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int. J. Radiat. Oncol. Biol. Phys., 2009, 73, 1069-1076.
139. Jing, Y.; Dai, J.; Chalmers-Redman, R.M.; Tatton, W.G.; Waxman, S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood, 1999, 94, 2102-2111.
140. Platanias, L.C. Biological responses to arsenic compounds. J. Biol. Chem., 2009, 284, 18583-18587.
141. Shen, Z.X.; Chen, G.Q.; Ni, J.H.; Li, X.S.; Xiong, S.M.; Qiu, Q.Y.; Zhu, J.; Tang, W.; Sun, G.L.; Yang, K.Q.; Chen, Y.; Zhou, L.; Fang, Z.W.; Wang, Y.T.; Ma, J.; Zhang, P.; Zhang, T.D.; Chen, S.J.; Chen, Z.; Wang, Z.Y. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood, 1997, 89, 3354-3360.
142. Soignet, S.L.; Maslak, P.; Wang, Z.G.; Jhanwar, S.; Calleja, E.; Dardashti, L.J.; Corso, D.; DeBlasio, A.; Gabrilove, J.; Scheinberg, D.A.; Pandolfi, P.P.; Warrell, R.P.J.J. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med., 1998, 339, 1341-1348.
143. Murphy, C.K.; Fey, E.J.; Watkins, B.A.; Wong, V.; Rothstein, D.; Sonis, ST. Efficacy of superoxide dismutase mimetic M40403 in attenuating radiation induced oral mucositis in hamsters. Clin. Cancer Res., 2008, 14, 4292-4297.
144. Harrison, M.R.; Hahn, N.M.; Pili, R.; Oh, W.K.; Hammers, H.; Sweeney, C.; Kim, K.; Perlman, S.; Arnott, J.; Sidor, C.; Wilding, G.; Liu, G. A phase II study of 2-methoxyestradiol (2ME2) nano crystal dispersion in patients with taxane refractory metastatic castrate resistant prostate cancer (CRPC). Invest. New Drugs, 2011, 29(6), 1465-1474.
145. Sweeney, C.; Liu, G.; Yiannoutsos, C.; Kolesar, J.; Horvath, D.; Staab, M.J.; Fife, K.; Armstrong, V.; Treston, A.; Sidor, C.; Wilding, G. A phase II multicentre, randomised, double blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin. Cancer Res., 2005, 11, 6625-6633.
146. Liu, G.; Botting, C.H.; Evans, K.M.; Walton, J.A.G.; Xu, G.; Slawin, A.M.Z.; Westwood, N.J. Optimisation of conoidin A, a peroxiredoxin inhibitor. Chem. Med. Chem., 2010, 5, 41-45.
147. Bar-Am, O.; Weinreb, O.; Amit, T.; Youdim, M.B.H. The novel cholinesterase-monoamine oxidase inhibitor and anti-oxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats. J. Mol. Neurosci., 2009, 37, 135-145.
148. Wang, T.; Tamae, D.; LeBon, T.; Shively, J.E.; Yen, Y.; Li, J.J. The role of peroxiredoxin II in radiation resistant MCF7 breast cancer cells. Cancer Res., 2005, 65, 10338-10346.
149. Bradshaw, T.D.; Matthews, C.S.; Cookson, J.; Chew, E.H.; Shah, M.; Bailey, K.; Monks, A.; Harris, E.; Westwell, A.D.; Wells, G.; Laughton, C.A.; Stevens, M.F.G. Elucidation of thioredoxin as a molecular target for antitumor quinols. Cancer Res., 2005, 65, 3911-3919.
150. Mukherjee, A.; Martin, S.G. The thioredoxin system: a key target in tumour and endothelial cells. Br. J. Pharmacol., 2007, 151, 1167-1175.
151. Kirkpatrick, D.L.; Jimale, M.L.; King, K.M.; Chen, T. Synthesis and evaluation of imidazolyl disulfides for selective cytotoxicity to hypoxic EMT6 tumor cells in vitro. Eur J. Med. Chem., 1992, 27, 33-37.
152. Ramanathan, R.K.; Abbruzzese, J.; Dragovich, T.; Kirkpatrick, L.; Guillen, J.M.; Baker, A.F.; Pestano, L.A.; Green, S.; VonHoff, D. A randomised phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression on gemcitabine containing combination. Cancer Chemother. Pharmacol., 2011, 67(3), 503-509.
153. Greenstein, J.P.; Venrette, W.V.; White, J. The liver catalase activity of tumour-bearing rats and the effect of extirpation of the tumours. J. Biol. Chem., 1941, 141, 327-328.
154. Margoliash, E.; Novogrodsky, A.; Schejter, A. Irreversible reaction of 3-amino-1:2:4-triazole and related inhibitors with the protein of catalase. Biochem. J., 1960, 74, 339-348.
155. Hiasa, Y.; Ohshima, M.; Kitahori, Y.; Yuassa, T.; Fujita, T.; Iwata, C. Promoting effects of 3-amino-1,2,4-triazole on the development of thyroid tumours in rats treated with N-bis(2-hydroxylpropyl)nitrosamine. Carcinogenesis, 1982, 3, 381-384.
156. Day, B.J. Catalase and glutathione peroxidase mimics. Biochem. Biopharmacol., 2009, 77, 285-296.
157. Fishel, M.L.; Kelley, M.R. the DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventative target. Mol. Aspects Med., 2007, 28, 375-395.
158. Nyland, R.L.; Luo, M.; Kelly, M.R.; Borch, R.F. Design and synthesis of novel quinone inhibitors targeted to the redox function of apurinic/apyrimidinic endonuclease/redox enhancing factor-1 (Ape1/Ref-1). J. Med. Chem., 2010, 53, 1200-1210.
159. Martin, S.A.; McCarthy, A.; Barber, L.J.; Burgess, D.J.; Parry, S.; Lord, C.J.; Ashworth, A. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol. Med., 2009, 1, 323-337.
160. Loft, S.; Møller, P.; Cooke, M.S.; Rozalski, R.; Olinski, R. Antioxidant vitamins and cancer risk: is oxidative damage to DNA a relevant biomarker. Eur. J. Nutr., 2008, 47(suppl. 2), 19-28.
161. Abbotts, R.; Madhusudan, S. Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer. Cancer Treat. Rev., 2010, 36(5), 425-435.